The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Stem Cell Therapy | Stem Cells